Print Page  Close Window

News Release

FierceBiotech names MyoKardia as one of its “Fierce 15” Biotech Companies of 2015

South San Francisco, CA – September 30, 2015 – MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has been named by FierceBiotech as one of 2015’s Fierce 15 biotechnology companies.

MyoKardia was incorporated in 2012 by Third Rock Ventures, in partnership with world-leading scientific and clinical researchers in cardiovascular genetics and muscle biology. Since MyoKardia’s inception, the company’s focus has been to discover and develop therapies for patients with heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia’s pipeline includes therapeutic programs for the chronic treatment of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). MyoKardia’s lead product candidate, MYK-461, is currently in Phase 1 clinical development.

“MyoKardia is honored to be recognized as a member of the ‘Fierce 15’ class of 2015 for our advancement of our novel precision medicine approach to the treatment of heritable cardiomyopathies, which are chronic and debilitating diseases that lead to significant unmet need for patients,” said Tassos Gianakakos, chief executive officer of MyoKardia. “This award is a testament to the innovative spirit and hard work of our employees in advancing our pipeline and our science, including moving our lead product candidate, MYK-461 into Phase 1 clinical development.”

The “Fierce 15” celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s thirteenth annual Fierce 15 selection. A complete list of “Fierce 15” companies can be found online at www.fiercebiotech.com/fierce15.

An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.

About MyoKardia

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate, MYK- 461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM and is currently being evaluated in three Phase 1 clinical trials. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of data from approximately 10,000 individuals, is the world’s largest registry of patients with heritable cardiomyopathies. MyoKardia’s purpose is to improve the lives of patients and families suffering from cardiovascular disease by creating targeted therapies that can change the course of their condition. For more information, please visit www.myokardia.com.

Media Contacts:
Katie Engleman
Pure Communications, Inc.
910-509-3977
katie@purecommunicationsinc.com